Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Macrogenics Licenses Antibody Technology
by Ann M. Thayer
November 1, 2010
| A version of this story appeared in
Volume 88, Issue 44
MacroGenics has signed two deals to develop drugs using its Dual-Affinity Re-Targeting antibody technology. With Boehringer Ingelheim, it will apply DART against up to 10 combinations of molecular targets in several disease areas. MacroGenics will receive $60 million in fees and R&D funding over three years and possibly $210 million in milestones for each of the 10 programs. Boehringer expects to make an equity investment in the company as well. MacroGenics also will work with Pfizer on two cancer targets for an undisclosed amount of R&D funding and milestone payments.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter